Fierce competition expected among hepatitis C therapies, triggered by Zepatier’s approval
Another competitor showed up in the Korean hepatitis C therapy market where Gilead and BMS are competing each other.
According to the industry concerned on the 22nd, the Korea MSD’s hepatitis C therapy ‘Zepatier(elbasvir/grazoprevir)’ recently acquired approval from the Ministry of Food and Drug...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
